Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -56.04% is 21% above its 5-year average of -71.35%, near the high end of its 5-year range (-799.78%–-30.69%).
As of the fiscal period ended Tuesday, June 30, 2026. 9.52% above its 12-month average of -61.94%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -56.04%.
RETURN ON EQUITY (ROE)
-56.04%
RETURN ON EQUITY (ROE) AVG TTM
-61.94%
RETURN ON EQUITY (ROE) AVG 3Y
-205.63%
RETURN ON EQUITY (ROE) AVG 5Y
-71.35%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+9.52%
CURRENT VS 3Y AVG
+72.75%
CURRENT VS 5Y AVG
+21.45%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.20%
median of 729 covered companies
CURRENT VS SECTOR MEDIAN
-36.03%
vs the sector median at left
PRF Technologies Ltd.
Market Cap
$72527.00
Return on Equity (ROE)
-56.04%
TTM Avg
-61.94%
3Y Avg
-205.63%
5Y Avg
-71.35%
Market Cap
$61172.00
Return on Equity (ROE)
N/A
TTM Avg
163.76%
3Y Avg
281.78%
5Y Avg
257.03%
Market Cap
$96046.00
Return on Equity (ROE)
N/A
TTM Avg
-12.94%
3Y Avg
110.91%
5Y Avg
74.52%
Market Cap
$109400.00
Return on Equity (ROE)
-31722.73%
TTM Avg
-22.71%
3Y Avg
4.16%
5Y Avg
21.87%
Market Cap
$30755.00
Return on Equity (ROE)
-124.31%
TTM Avg
-250.62%
3Y Avg
35.28%
5Y Avg
30.27%
Market Cap
$6241.00
Return on Equity (ROE)
N/A
TTM Avg
43.59%
3Y Avg
43.03%
5Y Avg
34.44%
Market Cap
$243502.00
Return on Equity (ROE)
-287.31%
TTM Avg
-182.19%
3Y Avg
-117.96%
5Y Avg
-131.39%
Market Cap
$389261.00
Return on Equity (ROE)
-5.89%
TTM Avg
-13.04%
3Y Avg
-24.95%
5Y Avg
-31.50%
Market Cap
$483178.00
Return on Equity (ROE)
-68.17%
TTM Avg
-111.11%
3Y Avg
-104.52%
5Y Avg
-88.82%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PRF Technologies Ltd. (PRFX) | $72527.00 | -56.04% | -61.94% | -205.63% | -71.35% |
| Akanda Corp. (AKAN)vs › | $61172.00 | N/A | 163.76% | 281.78% | 257.03% |
| Psyence Biomedical Ltd. (PBM)vs › | $96046.00 | N/A | -12.94% | 110.91% | 74.52% |
| Silexion Therapeutics Ltd. (SLXN)vs › | $109400.00 | -31722.73% | -22.71% | 4.16% | 21.87% |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $30755.00 | -124.31% | -250.62% | 35.28% | 30.27% |
| NewGenIvf Group Limited (NIVF)vs › | $6241.00 | N/A | 43.59% | 43.03% | 34.44% |
| SciSparc Ltd. (SPRC)vs › | $243502.00 | -287.31% | -182.19% | -117.96% | -131.39% |
| Niki BioSolutions, Inc. (NIKI)vs › | $389261.00 | -5.89% | -13.04% | -24.95% | -31.50% |
| XORTX Therapeutics Inc. (XRTX)vs › | $483178.00 | -68.17% | -111.11% | -104.52% | -88.82% |
| HCW Biologics Inc. (HCWB)vs › | $556226.00 | -66.26% | 77.79% | -17.48% | -22.53% |
ROE
-56.0%
ROA
-46.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -56.04% |
| 2026-03-31 | -54.53% |
| 2025-12-31 | -98.50% |
| 2025-09-30 | -52.23% |
| 2025-06-30 | -48.40% |
| 2025-03-31 | -121.28% |
| 2024-12-31 | -799.78% |
| 2024-03-31 | -678.68% |
| 2023-12-31 | -127.55% |
| 2023-09-30 | -86.65% |
| 2023-06-30 | -138.32% |
| 2023-03-31 | -104.01% |
| 2022-12-31 | -79.37% |
| 2022-09-30 | -54.67% |
| 2022-06-30 | -45.94% |
| 2022-03-31 | -41.31% |
| 2021-12-31 | -40.07% |
| 2021-09-30 | -33.44% |
| 2021-06-30 | -30.69% |
| 2021-03-31 | -23.52% |
| 2020-12-31 | -24.39% |
